2 files

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis

posted on 16.11.2020, 09:33 by Edward E. Neuberger, Ibrahim M. Abbass, Eddie Jones, Natalie J. Engmann

Article full text

The above summary slide and plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.